The U.S. Food and Drug Administration approved ViiV Healthcare’s Cabenuva as the only complete long-acting regimen for the treatment of HIV-1 infection in adults.

Once touted as promising treatments and by some even a cure, the World Health Organization dashes those claims, finding no benefit in the use of four popular Covid-19 treatments (remdesivir, hydroxychloroquine, lopinavir, or interferon-beta-1a) on hospitalized patients.